BAIBYS™ Fertility

We seek a System Engineer to lead the system engineering and testing of our AI-based autonomous robotics-based system for selecting ideal sperm for IVF. You will lead the test of a complex medical device that includes software and hardware. Please refer to the Career page on our website and send your CV to info@baibys.com. Thank you.

BAIBYS™, an innovator in AI-driven fertility solutions, today announced a major milestone with the United States Patent and Trademark Office (USPTO) issuing a Notice of Allowance for its "Automated Spermatozoa Candidate Identification" patent application. This strengthens BAIBYS™' intellectual property portfolio and underscores the company's development of technologies that transform IVF procedures. The allowed patent covers BAIBYS™ Fertility's proprietary artificial intelligence technology that revolutionizes the sperm analysis process, offering unprecedented accuracy and efficiency in identifying viable sperm candidates for assisted reproductive procedures. BAIBYS™' technology offers a faster, more efficient, and objective approach to sperm selection, utilizing AI and robotics to achieve higher pregnancy rates while reducing birth defects. This technology streamlines IVF workflows, saving embryologists valuable time and potentially increasing lab throughput. BAIBYS™ technology has the potential to reshape the fertility treatment market, which is projected to reach $110 billion by 2028. Addressing a critical need in this expanding market, BAIBYS™ offers fertility clinics and patients a more reliable and efficient solution for autonomous sperm analysis and selection. The company is currently in discussions with leading fertility clinics and healthcare providers for potential strategic partnerships and implementation of its technology. This patent allowance will contribute to additional commercialization opportunities while enhancing the company's overall value proposition.  Following recent CE marking, this patent further strengthens BAIBYS™'s position as a leader in the AI-driven fertility space, paving the way for continued growth and development. 

We are thrilled to announce that our BAIBYS™ system has received CE mark certification! This milestone enables us to bring advanced sperm selection technology to fertility clinics across Europe. Using high-powered microscopic magnification, BAIBYS™ performs precise sperm selection in accordance with WHO guidelines, integrating seamlessly into IVF treatment cycles. The system's enhanced capabilities aim to: - Improve IVF success rates - Reduce the risk of birth defects - Optimize treatment costs for clinics and patients This certification marks a significant step forward in our mission to advance fertility treatment standards. Follow us to learn more about how BAIBYS™ is transforming reproductive medicine. #IVF #FertilityTreatment #MedTech #ReproductiveMedicine #Innovation

We are sooooo proud to win a substantial grant of $500,000 from the Israel Innovation Authority רשות החדשנות for the 2nd year in a row. Especially during these times, the recognition of the Ministry of Innovation, Science and Technology IL | משרד החדשנות, המדע והטכנולוגיה is another significant seal of approval of the importance of BAIBYS™ Fertility's efforts to improve reproductive health globally. In a clinic near you, soon!

It is our great pleasure to spend our first marketing $$$ on this wonderful initiative. We are confident that the combined efforts of the organizations taking part will make #ivf better, more affordable and accessible, and make the world a better place with many more healthy babies and happier families.

We are so proud to have been selected, again, by Calcalist כלכליסט to participate in their Dream Team for the Mind The Tech LONDON event. It was our participation in their team at a similar event in Tokyo that led to our new collaboration with ROHTO Pharmaceutical Co., Ltd. We look forward to a productive and successful event this time as well.

BAIBYS raises $4.5M Series A for AI-based system that selects ideal sperm for fertility treatments Japanese pharmaceutical giant ROHTO joined the Israeli startup’s round as it prepares to begin sales this year. BAIBYS’ system examines sperm samples and automatically selects ideal sperm according to WHO criteria, both in terms of their motility and morphology. https://lnkd.in/dwXd-XJF

BAIBYS™ Fertility is excited to announce that we have joined the IVF Heroes Universe. We are proud to share our commitment to reducing the cost, time, and life disruption to a healthy baby, by offering a fully autonomous system (including the physical pickup) for sperm selection based on motility and morphology at high magnification. Learn more about the IVF Heroes Universe here, which will be published on October 17 by Inside Reproductive Health! #reproductivehealth #ivf #ivfheroesuniverse

BAIBYS™ Fertility Achieves ISO 13485:2016 Certification We are delighted to announce that BAIBYS™ Fertility has attained ISO 13485:2016 certification, a testament to our unwavering commitment to quality and safety in the medical device industry. This certification validates our robust quality management system, covering the design, development, manufacturing, and marketing of devices for fertility. By adhering to the stringent requirements of ISO 13485, we reinforce our dedication to developing and providing exceptional products and services to our customers.

We are extremely pleased to announce our new strategic investor, ROHTO Pharmaceutical Co., Ltd. (4527:Tokyo). Together, we can help #infertility patients better and sooner. https://lnkd.in/dUFgJe_J